Stefania Intoppa

Learn More
Tyrosine kinase inhibitors have profoundly modified the treatment and prognosis of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia. A rapid and accurate detection of the BCR-ABL fusion protein is paramount today for an optimal management of Ph(+) acute lymphoblastic leukemia. We have utilized a recently described and commercialized(More)
To the Editor We read with interest the article by Chang et al 1 in which the aberrant expression of nuclear p53 detected by immunohistochemical analysis in 10% or more of bone marrow biopsy cells of 14 of 110 patients affected by chronic lymphocytic leukemia (CLL) identified all but 1 case with del(17p) in 10% or more of cells by fluorescent in situ(More)
  • 1